

Paul Dent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/932290/publications.pdf>

Version: 2024-02-01

163
papers

14,045
citations

36271

51
h-index

20943

115
g-index

168
all docs

168
docs citations

168
times ranked

22676
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. <i>Nature</i> , 1990, 348, 302-308.	13.7	548
3	MAPK pathways in radiation responses. <i>Oncogene</i> , 2003, 22, 5885-5896.	2.6	529
4	Stress and Radiation-Induced Activation of Multiple Intracellular Signaling Pathways ¹ . <i>Radiation Research</i> , 2003, 159, 283-300.	0.7	437
5	Radiation-induced Release of Transforming Growth Factor β Activates the Epidermal Growth Factor Receptor and Mitogen-activated Protein Kinase Pathway in Carcinoma Cells, Leading to Increased Proliferation and Protection from Radiation-induced Cell Death. <i>Molecular Biology of the Cell</i> , 1999, 10, 2493-2506.	0.9	319
6	Radiation-induced cell signaling: inside-out and outside-in. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 789-801.	1.9	313
7	The role of cell signalling in the crosstalk between autophagy and apoptosis. <i>Cellular Signalling</i> , 2014, 26, 549-555.	1.7	297
8	Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance. <i>Cancer Research</i> , 2009, 69, 143-150.	0.4	273
9	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	1.3	239
10	Deoxycholic Acid (DCA) Causes Ligand-independent Activation of Epidermal Growth Factor Receptor (EGFR) and FAS Receptor in Primary Hepatocytes: Inhibition of EGFR/Mitogen-activated Protein Kinase-Signaling Module Enhances DCA-induced Apoptosis. <i>Molecular Biology of the Cell</i> , 2001, 12, 2629-2645.	0.9	218
11	The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress. <i>Molecular and Cellular Biology</i> , 2007, 27, 5499-5513.	1.1	209
12	Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases. <i>Science</i> , 1995, 268, 1902-1906.	6.0	199
13	Activation of Raf by ionizing radiation. <i>Nature</i> , 1996, 382, 813-816.	13.7	162
14	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. <i>Cancer Biology and Therapy</i> , 2008, 7, 1648-1662.	1.5	159
15	Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. <i>Oncogene</i> , 2002, 21, 4032-4041.	2.6	156
16	Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. <i>Oncogene</i> , 1998, 16, 2787-2796.	2.6	146
17	Ordered phosphorylation of p42mapk by MAP kinase kinase. <i>FEBS Letters</i> , 1992, 306, 17-22.	1.3	143
18	Coordinate Regulation of Stress- and Mitogen-Activated Protein Kinases in the Apoptotic Actions of Ceramide and Sphingosine. <i>Molecular Pharmacology</i> , 1997, 52, 935-947.	1.0	137

#	ARTICLE	IF	CITATIONS
19	Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. <i>Oncogene</i> , 1999, 18, 4756-4766.	2.6	133
20	Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. <i>Oncogene</i> , 2001, 20, 3266-3280.	2.6	121
21	Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. <i>Hepatology</i> , 2005, 42, 1291-1299.	3.6	115
22	HDAC inhibitors enhance the immunotherapy response of melanoma cells. <i>Oncotarget</i> , 2017, 8, 83155-83170.	0.8	108
23	Effects of ethanol on mitogen-activated protein kinase and stress-activated protein kinase cascades in normal and regenerating liver. <i>Biochemical Journal</i> , 1998, 334, 669-676.	1.7	106
24	Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation. <i>Clinical Cancer Research</i> , 2008, 14, 5385-5399.	3.2	99
25	Molecular mechanisms of radiation-induced accelerated repopulation. <i>Radiation Oncology Investigations</i> , 1999, 7, 321-330.	1.3	95
26	Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca ²⁺ -Dependent Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway. <i>Cancer Research</i> , 2010, 70, 6313-6324.	0.4	95
27	Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells. <i>Cancer Research</i> , 2011, 71, 4955-4967.	0.4	89
28	BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing. <i>Molecular Pharmacology</i> , 2009, 76, 327-341.	1.0	82
29	Crosstalk between ERK, AKT, and cell survival. <i>Cancer Biology and Therapy</i> , 2014, 15, 245-246.	1.5	82
30	CHK1 Inhibitors in Combination Chemotherapy: Thinking Beyond the Cell Cycle. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2011, 11, 133-140.	3.4	82
31	Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms. <i>Molecular Pharmacology</i> , 2009, 76, 342-355.	1.0	81
32	OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells. <i>Molecular Pharmacology</i> , 2006, 70, 589-603.	1.0	80
33	Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2220-2231.	1.9	79
34	GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. <i>Journal of Cellular Physiology</i> , 2015, 230, 1661-1676.	2.0	79
35	Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2010, 10, 903-917.	1.5	72
36	Multisite phosphorylation of the glycogen-binding subunit of protein phosphatase-1G by cyclic AMP-dependent protein kinase and glycogen synthase kinase-3. <i>FEBS Letters</i> , 1989, 248, 67-72.	1.3	70

#	ARTICLE	IF	CITATIONS
37	Targetting of protein phosphatase 1 to the sarcoplasmic reticulum of rabbit skeletal muscle by a protein that is very similar or identical to the G subunit that directs the enzyme to glycogen. FEBS Journal, 1990, 189, 243-249.	0.2	69
38	Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells. Molecular Pharmacology, 2014, 85, 408-419.	1.0	69
39	Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood, 2005, 105, 1706-1716.	0.6	65
40	Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice. Biochemical Journal, 1998, 336, 551-560.	1.7	64
41	Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene, 2019, 38, 5890-5904.	2.6	63
42	Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene, 1997, 15, 53-61.	2.6	62
43	The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation. Molecular Pharmacology, 2007, 72, 788-795.	1.0	61
44	Ionizing Radiation Causes a Dose-Dependent Release of Transforming Growth Factor β In vitro from Irradiated Xenografts and during Palliative Treatment of Hormone-Refractory Prostate Carcinoma. Clinical Cancer Research, 2004, 10, 5724-5731.	3.2	60
45	Hepatitis B virus X protein increases expression of p21Cip-1/WAF1/MDA6 and p27Kip-1 in primary mouse hepatocytes, leading to reduced cell cycle progression. Hepatology, 2001, 34, 906-917.	3.6	59
46	Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Molecular Cancer Therapeutics, 2005, 4, 257-70.	1.9	58
47	Histone Deacetylase Inhibitors Activate NF- κ B in Human Leukemia Cells through an ATM/NEMO-related Pathway. Journal of Biological Chemistry, 2010, 285, 10064-10077.	1.6	57
48	HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i> . Oncotarget, 2017, 8, 90262-90277.	0.8	57
49	Characterization of Cdk955 and differential regulation of two Cdk9 isoforms. Gene, 2005, 350, 51-58.	1.0	56
50	Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis, 2015, 36, S2-S18.	1.3	55
51	The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 16367-16386.	0.8	55
52	The development of MDA-7/IL-24 as a cancer therapeutic. , 2010, 128, 375-384.		54
53	PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biology and Therapy, 2013, 14, 458-465.	1.5	53
54	Regulation of mda-7 gene expression during human melanoma differentiation. Oncogene, 2000, 19, 1362-1368.	2.6	51

#	ARTICLE	IF	CITATIONS
55	GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. <i>Journal of Cellular Physiology</i> , 2015, 230, 2552-2578.	2.0	51
56	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 758-767.	1.5	48
57	The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib. <i>Seminars in Cancer Biology</i> , 2020, 66, 129-139.	4.3	46
58	Identification of three in vivo phosphorylation sites on the glycogen-binding subunit of protein phosphatase 1 from rabbit skeletal muscle, and their response to adrenaline. <i>FEBS Letters</i> , 1990, 259, 281-285.	1.3	45
59	Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. <i>Biochemical Journal</i> , 1996, 314, 401-404.	1.7	45
60	Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells. <i>Cancer Biology and Therapy</i> , 2002, 1, 243-253.	1.5	45
61	Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. <i>Drug Resistance Updates</i> , 2009, 12, 65-73.	6.5	45
62	OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. <i>Cancer Biology and Therapy</i> , 2012, 13, 224-236.	1.5	45
63	Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic. <i>Frontiers in Oncology</i> , 2016, 6, 142.	1.3	45
64	AP-1 and C/EBP transcription factors contribute to mdm-7 gene promoter activity during human melanoma differentiation. <i>Journal of Cellular Physiology</i> , 2000, 185, 36-46.	2.0	44
65	Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 2281-2298.	2.0	44
66	Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. <i>Oncotarget</i> , 2016, 7, 12975-12996.	0.8	44
67	The afatinib resistance of <i>in vivo</i> generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. <i>Oncotarget</i> , 2016, 7, 19620-19630.	0.8	43
68	Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. <i>Blood</i> , 2011, 118, 5189-5200.	0.6	42
69	Pazopanib and HDAC inhibitors interact to kill sarcoma cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 578-585.	1.5	42
70	Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2384-2398.	1.9	42
71	OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. <i>Journal of Cellular Physiology</i> , 2015, 230, 1982-1998.	2.0	42
72	[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells. <i>Cancer Biology and Therapy</i> , 2017, 18, 705-714.	1.5	41

#	ARTICLE	IF	CITATIONS
73	PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. <i>Oncotarget</i> , 2017, 8, 1449-1468.	0.8	41
74	Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. <i>Oncotarget</i> , 2016, 7, 4399-4413.	0.8	40
75	AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication. <i>Biochemical Pharmacology</i> , 2020, 182, 114227.	2.0	39
76	AR12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. <i>Journal of Cellular Physiology</i> , 2016, 231, 2286-2302.	2.0	38
77	Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1095-1100.	1.9	38
78	Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G12V and G13V and kill uveal melanoma cells. <i>Cancer Biology and Therapy</i> , 2019, 20, 700-710.	1.5	37
79	Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3101-3112.	1.9	33
80	Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells. <i>Molecular Pharmacology</i> , 2010, 78, 909-917.	1.0	33
81	TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. <i>Autophagy</i> , 2018, 14, 1-16.	4.3	33
82	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. <i>Cancer Biology and Therapy</i> , 2018, 19, 132-137.	1.5	32
83	Neratinib augments the lethality of [regorafenib+sildenafil]. <i>Journal of Cellular Physiology</i> , 2019, 234, 4874-4887.	2.0	32
84	Positive and negative regulation of JNK1 by protein kinase C and p42MAP kinase in adult rat hepatocytes. <i>FEBS Letters</i> , 1997, 412, 9-14.	1.3	31
85	Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors. <i>Molecular Pharmacology</i> , 2012, 82, 322-332.	1.0	31
86	(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-EPD1 therapies in vivo. <i>Journal of Cellular Physiology</i> , 2020, 235, 6862-6874.	2.0	29
87	1-Adrenergic inhibition of proliferation in HepG2 cells stably transfected with the 1B-adrenergic receptor through a p42MAP kinase/p21Cip1/WAF1-dependent pathway. <i>FEBS Letters</i> , 1998, 436, 131-138.	1.3	27
88	Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling. <i>Journal of Cellular Physiology</i> , 2020, 235, 7889-7899.	2.0	27
89	[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NF-B compensatory survival signaling. <i>Oncotarget</i> , 2016, 7, 23608-23632.	0.8	27
90	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 525-533.	1.5	26

#	ARTICLE	IF	CITATIONS
91	Genetic Evidence That Stress-Activated p38 MAP Kinase Is Necessary but Not Sufficient for UV Activation of HIV Gene Expression. <i>Biochemistry</i> , 1999, 38, 13055-13062.	1.2	23
92	The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 786-796.	1.5	23
93	GZ17.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy. <i>Journal of Cellular Physiology</i> , 2020, 235, 8098-8113.	2.0	23
94	[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. <i>Oncotarget</i> , 2018, 9, 6062-6074.	0.8	23
95	Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 40398-40417.	0.8	23
96	Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 567-574.	1.5	22
97	MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy?. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 712-719.	1.2	21
98	Radiation-Stimulated ERK1/2 and JNK1/2 Signaling can Promote Cell Cycle Progression in Human Colon Cancer Cells. <i>Cell Cycle</i> , 2005, 4, 456-464.	1.3	21
99	Differential regulation of autophagy and cell viability by ceramide species. <i>Cancer Biology and Therapy</i> , 2015, 16, 733-742.	1.5	21
100	Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 649-654.	0.6	21
101	Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. <i>Biochemical Pharmacology</i> , 2005, 70, 1685-1696.	2.0	20
102	Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death <i>in vivo</i> and prolonged suppression of tumor re-growth. <i>Cancer Biology and Therapy</i> , 2005, 4, 1275-1284.	1.5	20
103	Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 1660-1670.	1.5	20
104	Signaling alterations caused by drugs and autophagy. <i>Cellular Signalling</i> , 2019, 64, 109416.	1.7	20
105	Searching for a cure: Gene therapy for glioblastoma. <i>Cancer Biology and Therapy</i> , 2008, 7, 1335-1340.	1.5	19
106	Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. <i>Cancer Biology and Therapy</i> , 2019, 20, 109-121.	1.5	19
107	Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 616-629.	1.9	18
108	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. <i>Oncotarget</i> , 2016, 7, 17290-17300.	0.8	18

#	ARTICLE	IF	CITATIONS
109	Neratinib decreases pro-survival responses of [sorafenib+Âvorinostat] in pancreatic cancer. <i>Biochemical Pharmacology</i> , 2020, 178, 114067.	2.0	17
110	H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 243-55.	1.9	17
111	Not the comfy chair! Cancer drugs that act against multiple active sites. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 893-901.	1.5	15
112	The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. <i>Cellular Signalling</i> , 2020, 70, 109573.	1.7	15
113	Dissecting the Roles of Checkpoint Kinase 1/CDC2 and Mitogen-Activated Protein Kinase Kinase 1/2/Extracellular Signal-Regulated Kinase 1/2 in Relation to 7-Hydroxystaurosporine-Induced Apoptosis in Human Multiple Myeloma Cells. <i>Molecular Pharmacology</i> , 2006, 70, 1965-1973.	1.0	12
114	Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. <i>Molecular Pharmacology</i> , 2015, 88, 512-523.	1.0	12
115	Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. <i>Biochemical Pharmacology</i> , 2021, 190, 114642.	2.0	12
116	A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses. <i>Journal of Dermatological Treatment</i> , 2022, 33, 590-591.	1.1	11
117	PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. <i>Oncotarget</i> , 2017, 8, 13464-13475.	0.8	11
118	The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib. <i>Frontiers in Oncology</i> , 2019, 9, 650.	1.3	10
119	GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling. <i>Frontiers in Oncology</i> , 2020, 10, 1331.	1.3	10
120	GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 656453.	1.3	10
121	GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins. <i>Frontiers in Oncology</i> , 2021, 11, 711043.	1.3	10
122	Valproate augments Niraparib killing of tumor cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 797-808.	1.5	10
123	Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells. <i>Advances in Cancer Research</i> , 2018, 137, 1-15.	1.9	9
124	Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition. <i>Cancer Biology and Therapy</i> , 2019, 20, 157-168.	1.5	9
125	Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition. <i>Cancer Biology and Therapy</i> , 2019, 20, 597-607.	1.5	9
126	Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43. <i>Aging</i> , 2021, 13, 17097-17117.	1.4	9

#	ARTICLE	IF	CITATIONS
127	Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change.. Blood, 2004, 104, 1995-1995.	0.6	9
128	GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. Oncotarget, 2022, 13, 92-104.	0.8	9
129	Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment. Molecular Pharmacology, 2007, 71, 259-275.	1.0	8
130	Reversing Translational Suppression and Induction of Toxicity in Pancreatic Cancer Cells Using a Chemoprevention Gene Therapy Approach. Molecular Pharmacology, 2015, 87, 286-295.	1.0	8
131	Repurposing Tecfidera for cancer. Aging, 2016, 8, 1289-1290.	1.4	8
132	NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells. Oncology Signaling, 2018, 1, 19-30.	0.2	8
133	PI3K: a rational target for ovarian cancer therapy?. Cancer Biology and Therapy, 2009, 8, 27-30.	1.5	7
134	AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins. Journal of Clinical & Cellular Immunology, 2016, 7, .	1.5	7
135	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biology and Therapy, 2018, 19, 239-247.	1.5	7
136	Fingolimod Augments Monomethylfumarate Killing of GBM Cells. Frontiers in Oncology, 2020, 10, 22.	1.3	7
137	Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget, 0, 7, 42625-42638.	0.8	7
138	Non-canonical p53 signaling to promote invasion. Cancer Biology and Therapy, 2013, 14, 879-880.	1.5	6
139	Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. Cellular Signalling, 2020, 68, 109525.	1.7	6
140	New methods to control neuroblastoma growth. Cancer Biology and Therapy, 2014, 15, 481-482.	1.5	5
141	Metabolism of Histone Deacetylase Proteins Oponizes Tumor Cells to Checkpoint Inhibitory Immunotherapies. Immunometabolism, 2020, 2, .	0.7	5
142	Irofulven: Resurgence for alkylating therapy in cancer?. Cancer Biology and Therapy, 2004, 3, 1143-1144.	1.5	4
143	GZ17-6.02 and axitinib interact to kill renal carcinoma cells. Oncotarget, 2022, 13, 281-290.	0.8	4
144	Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology and Therapy, 2008, 7, 587-593.	1.5	3

#	ARTICLE	IF	CITATIONS
145	Neratinib kills Bâ€RAF V600E melanoma via ROSâ€dependent autophagosome formation and death receptor signaling. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 66-77.	1.5	3
146	Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate.. <i>Blood</i> , 2007, 110, 1041-1041.	0.6	3
147	Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism.. <i>Blood</i> , 2009, 114, 297-297.	0.6	3
148	Ribonucleotide Reductase Inhibition: Regulation of the Radiosensitive Phenotype via NFkB and Bcl-2. <i>Cancer Biology and Therapy</i> , 2002, 1, 546-547.	1.5	2
149	The Regulation of Tumor Suppressor Genes by Oncogenes. , 2003, 222, 269-292.		2
150	DMC: Novel celecoxib derivatives to rap cancer. <i>Cancer Biology and Therapy</i> , 2005, 4, 583-584.	1.5	2
151	Met in lung cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 653-654.	1.5	2
152	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. <i>Anti-Cancer Drugs</i> , 2021, 32, 779-785.	0.7	2
153	Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 723966.	1.3	2
154	Molecular mechanisms of radiationâ€induced accelerated repopulation. <i>Radiation Oncology Investigations</i> , 1999, 7, 321-330.	1.3	2
155	Mechanisms of GZ17-6.02 resistance. <i>Anti-Cancer Drugs</i> , 2022, 33, 415-423.	0.7	2
156	Not so WEE. <i>Cancer Biology and Therapy</i> , 2014, 15, 351-352.	1.5	1
157	APâ€1 and C/EBP transcription factors contribute to mdaâ€7 gene promoter activity during human melanoma differentiation. <i>Journal of Cellular Physiology</i> , 2000, 185, 36-46.	2.0	1
158	Minting a new class of Polo-like-kinase inhibitors. <i>Cancer Biology and Therapy</i> , 2009, 8, 2384-2385.	1.5	0
159	Cell Signaling and Translational Developmental Therapeutics. , 2021, , .		0
160	Chemotherapy resistance and YY1. , 2021, , 243-249.		0
161	Kinase inhibitors: look beyond the label on the bottle. , 2019, 2, 1032-1043.		0
162	OBSOLETE: Cell Signaling and Translational Developmental Therapeutics. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
163	Approaches for Monitoring Signal Transduction Changes in Normal and Cancer Cells. , 2007, 383, 259-276.		0